<DOC>
	<DOCNO>NCT00004893</DOCNO>
	<brief_summary>RATIONALE : Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill breast cancer cell . PURPOSE : Randomized phase II trial study effectiveness interleukin-12 treating patient metastatic recurrent breast cancer .</brief_summary>
	<brief_title>Interleukin-12 Treating Patients With Metastatic Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine activity interleukin-12 define percentage patient progress 6 month therapy . II . Compare percentage patient progress six month without treatment regimen . III . Determine time progression overall survival patient population treatment . OUTLINE : This randomize study . Patients stratify accord disease free interval primary diagnosis first metastasis ( less 3 year vs 3 year longer ) , estrogen receptor status ( positive v negative ) , disease status ( complete response , partial response , detectable disease , stable disease ) . Patients randomize one two treatment arm . Arm I : Patients begin therapy sooner 3 week later 6 week since last chemotherapy dose . Patients receive interleukin-12 subcutaneously twice week . Treatment continue absence disease progression unacceptable toxicity . Patients follow least every 3 month 1 year . If progression 1 year , may follow need new sign symptom survival 5 year . Arm II : Patients observe 6 month . If disease progress first 6 month , patient may receive interleukin-12 arm I . Patients without disease progression within first 6 month may also receive interleukin-12 arm I . Treatment continue absence disease progression unacceptable toxicity . Patients follow toxicity interleukin-12 discontinue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent breast cancer ( confine breast ) One prior induction chemotherapy regimen recurrent metastatic disease ( 4 week treatment 46 course ) result stable disease , partial response , complete response Pleural peritoneal effusion palliate induction chemotherapy allow No uncontrolled brain metastasis Previously treat brain metastasis allow : No evidence progression least 3 month follow radiotherapy and/or surgical treatment AND At least 30 day since dexamethasone corticosteroid AND Other metastatic site exist No bone marrow brain site metastases No meningeal disease Hormone receptor status Estrogen receptor status know PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Menopausal status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Hemoglobin least 9 g/dL ( transfusion epoetin alfa allow ) Platelet count least 100,000/mm3 Hepatic : SGOT/SGPT great 1.5 time upper limit normal ( ULN ) Albumin least 3.0 g/dL Bilirubin great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Creatinine clearance least 60 mL/min Other : No active malignancy except nonmelanoma skin cancer Not pregnant nursing Fertile patient must use effective contraception No inflammatory bowel disease active gastric ulcer No prior autoimmune disease immunodeficiency syndrome PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy No concurrent interleukin11 Chemotherapy : See Disease Characteristics No concurrent chemotherapy Prior chemotherapy bone marrow progenitor support ( bone marrow transplant and/or peripheral blood stem cell support ) allow adjuvant setting ( metastasis ) Endocrine therapy : Prior hormone therapy breast cancer allow No concurrent hormones allow except noncancer cancer treatment relate condition ( e.g . insulin diabetes ) No concurrent dexamethasone steroidal antiemetic Radiotherapy : Prior radiotherapy allow No concurrent radiotherapy Surgery : Not specify Other : Prior bisphosphonate therapy allow start least 3 month study No initiation bisphosphonate therapy study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>